Calcium channel blockers suppress cytokine-induced activation of human neutrophils

American Journal of Hypertension

Volumn 21, Issue 1, 2008, Pages 78-84

  Shima, Etsuko ^a   Katsube, Masataka ^a   Kato, Takayuki ^a   Kitagawa, Maki ^a   Hato, Fumihiko ^a   Hino, Masayuki ^a   Takahashi, Tatsuji ^a   Fujita, Hisakazu ^a   Kitagawa, Seiichi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CYTOKINE; DILTIAZEM; EFONIDIPINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICARDIPINE; NIFEDIPINE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPERTENSION; LEUKOCYTE ACTIVATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; NEUTROPHIL ACTIVATION; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38349147663     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2007.13     Document Type: Article

References (31)

1. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23:2155-2163.
2. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97:576-580.
3. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 1999; 33:242-249.
4. Stepien O, Gogusev J, Zhu DL, Iouzalen L, Herembert T, Drueke TB, Marche P. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31:786-793.
5. Hirata A, Igarashi M, Yamaguchi H, Suwabe A, Daimon M, Kato T, Tominaga M. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br J Pharmacol 2000; 131:1521-1530.
6. Chou TC, Li CY, Yen MH, Ding YA. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process. Biochem Pharmacol 1999; 58:1657-1663.
7. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31:275-281.
8. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-2225.
9. 2+ content after activation in essential hypertension. Hypertension 2000; 36:813-817.
10. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44:1945-1956.
11. Parissis JT, Venetsanou KF, Kalantzi MV, Mentzikof DD, Karas SM. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol 2000; 85:777-779.
12. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997; 131:79-84.
13. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
14. Takahashi M, Kitagawa S, Masuyama JI, Ikeda U, Kasahara T, Takahashi YI, Furukawa Y, Kano S, Shimada K. Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor. Circulation 1996; 93:1185-1193.
15. Takahashi T, Hato F, Yamane T, Fukumasu H, Suzuki K, Ogita S, Nishizawa Y, Kitagawa S. Activation of human neutrophil by cytokine-activated endothelial cells. Circ Res 2001; 88:422-429.
16. Yuo A, Kitagawa S, Motoyoshi K, Azuma E, Saito M, Takaku F. Rapid priming of human monocytes by human hematopoietic growth factors: granulocyte- macrophage colony-stimulating factor (CSF), macrophage-CSF, and interleukin-3 selectively enhance superoxide release triggered by receptor-mediated agonists. Blood 1992; 79:1553-1557.
17. 2+-mobilizing agonists. J Immunol 1989; 142:1678-1684.
18. Suzuki K, Hino M, Hato F, Tatsumi N, Kitagawa S. Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-α. Blood 1999; 93:341-349.
19. Suzuki K, Hasegawa T, Sakamoto C, Zhou Y-M, Hato F, Hino M, Tatsumi N, Kitagawa S. Cleavage of mitogen-activated protein kinases in human neutrophils undergoing apoptosis: role in decreased responsiveness to inflammatory cytokines. J Immunol 2001; 166:1185-1192.
20. Suzuki K, Hino M, Kutsuna H, Hato F, Sakamoto C, Takahashi T, Tatsumi N, Kitagawa S. Selective activation of p38 mitogen-activated protein kinase cascade in human neutrophils stimulated by IL-1β. J Immunol 2001; 167:5940-5947.
21. Kamata N, Kutsuna H, Hato F, Kato T, Oshitani N, Arakawa T, Kitagawa S. Activation of human neutrophils by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor α: role of phosphatidylinositol 3-kinase. Int J Hematol 2004; 80:421-427.
22. Nakamae-Akahori M, Kato T, Masuda S, Sakamoto E, Kutsuna H, Hato F, Nishizawa Y, Hino M, Kitagawa S. Enhanced neutrophil motility by granulocyte colony-stimulating factor: the role of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. Immunology 2006; 119:393-403.
23. Rayment NB, Moss E, Faulkner L, Brickell PM, Davies MJ, Woolf N, Katz DR. Synthesis of TNFα and TGFβ mRNA in the different micro-environments within atheromatous plaques. Cardiovasc Res 1996; 32:1123-1130.
24. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33:2398-2408.
25. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006; 35:821-836.
26. Bondeva T, Pirola L, Bulgarelli-Leva G, Rubio I, Wetzker R, Wymann MP. Bifurcation of lipid and protein kinase signals of PI3Kγ to the protein kinases PKB and MAPK. Science 1998; 282:293-296.
27. Zhou Y, Kutsuna H, Suzuki K, Hato F, Kitagawa S. Serine protease inhibitors inhibit superoxide release and adherence in human neutrophils stimulated by granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α. Int J Hematol 2003; 77:253-258.
28. 2+ influx in human neutrophils using the patch clamp technique. Schweiz Med Wochenschr 1995; 125:1174-1178.
29. Khalfi F, Gressier B, Brunet C, Dine T, Luyckx M, Cazin M, Cazin JC. Effects of calcium antagonist diltiazem on leukocyte elastase and on reactive oxygen species production in human neutrophils. Pharmacol Res 1996; 33:117-122.
30. Khalfi F, Gressier B, Dine T, Brunet C, Luyckx M, Ballester L, Cazin M, Cazin JC. Verapamil inhibits elastase release and superoxide anion production in human neutrophils. Biol Pharm Bull 1998; 21:109-112.
31. Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L, Cazin JC. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils - a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther 2002; 16:515-520.